MIM
DAWN

MetLife Investment Management’s Day One Biopharmaceuticals DAWN Stock Holding History

MetLife Investment Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$946K Buy
44,101
+437
+1% +$6.16K ﹤0.01% 1421
2025
Q4 		$407K Buy
43,664
+6,186
+17% +$51.7K ﹤0.01% 1886
2025
Q3 		$264K Sell
37,478
-6,964
-16% -$47.9K ﹤0.01% 2155
2025
Q2 		$289K Buy
44,442
+10,832
+32% +$74.5K ﹤0.01% 1979
2025
Q1 		$267K Sell
33,610
-638
-2% -$6.87K ﹤0.01% 2045
2024
Q4 		$434K Buy
34,248
+3,781
+12% +$52.6K ﹤0.01% 1882
2024
Q3 		$424K Hold
30,467
– – ﹤0.01% 1867
2024
Q2 		$420K Sell
30,467
-2,976
-9% -$43.5K ﹤0.01% 1825
2024
Q1 		$552K Hold
33,443
– – ﹤0.01% 1623
2023
Q4 		$488K Hold
33,443
– – ﹤0.01% 1693
2023
Q3 		$410K Buy
33,443
+7,037
+27% +$91.8K ﹤0.01% 1754
2023
Q2 		$315K Buy
26,406
+10,833
+70% +$141K ﹤0.01% 1979
2023
Q1 		$208K Hold
15,573
– – ﹤0.01% 2195
2022
Q4 		$335K Hold
15,573
– – ﹤0.01% 1898
2022
Q3 		$312K Hold
15,573
– – ﹤0.01% 1992
2022
Q2 		$279K Hold
15,573
– – ﹤0.01% 2068
2022
Q1 		$154K Buy
+15,573
New +$206K ﹤0.01% 2499
2021
Q4 		– Sell
-4,806
Closed -$114K – 2511
2021
Q3 		$114K Buy
+4,806
New +$115K ﹤0.01% 2383

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

MetLife Investment Management's DAWN Position: Q1 2026 in Review

MetLife Investment Management increased its Day One Biopharmaceuticals (DAWN) stake by 1% in Q1 2026, buying an estimated $6.16K and bringing the position to 44,101 shares worth $946K. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

MetLife Investment Management first reported a position in DAWN in Q3 2021 and has held it in 18 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • MetLife Investment Management held 44,101 shares of Day One Biopharmaceuticals worth $946K as of Q1 2026.
  • MetLife Investment Management bought 437 Day One Biopharmaceuticals shares in Q1 2026, an estimated $6.16K.
  • Day One Biopharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1421 holding.
  • MetLife Investment Management first reported a position in Day One Biopharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.